347 related articles for article (PubMed ID: 33547201)
21. A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors.
Santana VM; Sahr N; Tatevossian RG; Jia S; Campagne O; Sykes A; Stewart CF; Furman WL; McGregor LM
Cancer; 2020 Apr; 126(8):1749-1757. PubMed ID: 31967673
[TBL] [Abstract][Full Text] [Related]
22. A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.
Infante JR; Cassier PA; Gerecitano JF; Witteveen PO; Chugh R; Ribrag V; Chakraborty A; Matano A; Dobson JR; Crystal AS; Parasuraman S; Shapiro GI
Clin Cancer Res; 2016 Dec; 22(23):5696-5705. PubMed ID: 27542767
[TBL] [Abstract][Full Text] [Related]
23. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of everolimus in pediatric patients with refractory solid tumors.
Fouladi M; Laningham F; Wu J; O'Shaughnessy MA; Molina K; Broniscer A; Spunt SL; Luckett I; Stewart CF; Houghton PJ; Gilbertson RJ; Furman WL
J Clin Oncol; 2007 Oct; 25(30):4806-12. PubMed ID: 17947729
[TBL] [Abstract][Full Text] [Related]
25. A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
Schmid P; Sablin MP; Bergh J; Im SA; Lu YS; Martínez N; Neven P; Lee KS; Morales S; Pérez-Fidalgo JA; Adamson D; Gonçalves A; Prat A; Jerusalem G; Schlieker L; Espadero RM; Bogenrieder T; Huang DC; Crown J; Cortés J
Breast Cancer Res; 2021 Jan; 23(1):8. PubMed ID: 33451345
[TBL] [Abstract][Full Text] [Related]
26. A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer.
Besse B; Heist RS; Papadmitrakopoulou VA; Camidge DR; Beck JT; Schmid P; Mulatero C; Miller N; Dimitrijevic S; Urva S; Pylvaenaeinen I; Petrovic K; Johnson BE
Ann Oncol; 2014 Feb; 25(2):505-11. PubMed ID: 24368401
[TBL] [Abstract][Full Text] [Related]
27. Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors.
Morgan RJ; Synold T; Mamelak A; Lim D; Al-Kadhimi Z; Twardowski P; Leong L; Chow W; Margolin K; Shibata S; Somlo G; Yen Y; Frankel P; Doroshow JH
Cancer Chemother Pharmacol; 2010 Oct; 66(5):927-33. PubMed ID: 20107803
[TBL] [Abstract][Full Text] [Related]
28. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
[TBL] [Abstract][Full Text] [Related]
29. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
Fouladi M; Park JR; Stewart CF; Gilbertson RJ; Schaiquevich P; Sun J; Reid JM; Ames MM; Speights R; Ingle AM; Zwiebel J; Blaney SM; Adamson PC
J Clin Oncol; 2010 Aug; 28(22):3623-9. PubMed ID: 20606092
[TBL] [Abstract][Full Text] [Related]
30. A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
Qayed M; Cash T; Tighiouart M; MacDonald TJ; Goldsmith KC; Tanos R; Kean L; Watkins B; Suessmuth Y; Wetmore C; Katzenstein HM
Pediatr Blood Cancer; 2020 Apr; 67(4):e28134. PubMed ID: 31876107
[TBL] [Abstract][Full Text] [Related]
31. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.
Fury MG; Sherman E; Haque S; Korte S; Lisa D; Shen R; Wu N; Pfister D
Cancer Chemother Pharmacol; 2012 Mar; 69(3):591-8. PubMed ID: 21913034
[TBL] [Abstract][Full Text] [Related]
32. A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy.
Weinberg BA; Wang H; Witkiewicz AK; Marshall JL; He AR; Vail P; Knudsen ES; Pishvaian MJ
J Pancreat Cancer; 2020; 6(1):45-54. PubMed ID: 32642630
[No Abstract] [Full Text] [Related]
33. Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.
Navid F; Baker SD; McCarville MB; Stewart CF; Billups CA; Wu J; Davidoff AM; Spunt SL; Furman WL; McGregor LM; Hu S; Panetta JC; Turner D; Fofana D; Reddick WE; Leung W; Santana VM
Clin Cancer Res; 2013 Jan; 19(1):236-46. PubMed ID: 23143218
[TBL] [Abstract][Full Text] [Related]
34. A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).
Cash T; Fox E; Liu X; Minard CG; Reid JM; Scheck AC; Weigel BJ; Wetmore C
Pediatr Blood Cancer; 2021 Sep; 68(9):e29065. PubMed ID: 33881209
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.
Lulla RR; Goldman S; Yamada T; Beattie CW; Bressler L; Pacini M; Pollack IF; Fisher PG; Packer RJ; Dunkel IJ; Dhall G; Wu S; Onar A; Boyett JM; Fouladi M
Neuro Oncol; 2016 Sep; 18(9):1319-25. PubMed ID: 27022131
[TBL] [Abstract][Full Text] [Related]
36. Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
Miller TW; Traphagen NA; Li J; Lewis LD; Lopes B; Asthagiri A; Loomba J; De Jong J; Schiff D; Patel SH; Purow BW; Fadul CE
J Neurooncol; 2019 Sep; 144(3):563-572. PubMed ID: 31399936
[TBL] [Abstract][Full Text] [Related]
37. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
[TBL] [Abstract][Full Text] [Related]
38. SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS).
Movva S; Matloob S; Handorf EA; Choy E; Merriam P; Flieder DB; Cai KQ; Zhou Y; Tetzlaff ED; Pagan C; Barker E; Veggeberg R; Zumpano D; Rink L; von Mehren M; George S
Clin Cancer Res; 2024 Jan; 30(2):315-322. PubMed ID: 37967116
[TBL] [Abstract][Full Text] [Related]
39. A Phase I Study of sequences of the CDK4/6 Inhibitor, Ribociclib Combined with Gemcitabine in Patients with Advanced Solid Tumors.
Seetharam M; Norman A; Allred J; Kong J; Opyrchal M; Ma WW; Lou Y; Dy GK; Mahipal A; Weroha J; Wahner-Hendrickson A; Reid JM; Adjei AA
Res Sq; 2024 Apr; ():. PubMed ID: 38746220
[TBL] [Abstract][Full Text] [Related]
40. CNS penetration of the CDK4/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors.
Patel YT; Davis A; Baker SJ; Campagne O; Stewart CF
Cancer Chemother Pharmacol; 2019 Aug; 84(2):447-452. PubMed ID: 31079218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
